Authors: Salmon-Ceron, D Excler, JL Finkielsztein, L Autran, B Gluckman, JC Sicard, D Matthews, TJ Meignier, B Valentin, C El Habib, R Blondeau, C Raux, M Moog, C Tartaglia, J Chong, P Klein, M Milcamps, B Heshmati, F Plotkin, S

Citation: D. Salmon-ceron et al., Safety and immunogenicity of a live recombinant canarypox virus expressingHIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection, AIDS RES H, 15(7), 1999, pp. 633-645

Authors: Mira, JP Cariou, A Grall, F Delclaux, C Losser, MR Heshmati, F Cheval, C Monchi, M Teboul, JL Riche, F Leleu, G Arbibe, L Mignon, A Delpech, M Dhainaut, JF

Citation: Jp. Mira et al., Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality - A multicenter study, J AM MED A, 282(6), 1999, pp. 561-568

Authors: Breban, M Dougados, M Picard, F Zompi, S Marolleau, JP Bocaccio, C Heshmati, F Mezieres, M Dreyfus, F Bouscary, D

Citation: M. Breban et al., Intensified-dose (4 gm/m(2)) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis, ARTH RHEUM, 42(11), 1999, pp. 2275-2280